Multiple Sclerosis. Multiple Sclerosis. In addition to help nursing professional to understand the signs and
|
|
- Ashlyn Charles
- 8 years ago
- Views:
Transcription
1 How to Receive Your CE Credits Read your selected course Completed the quiz at the end of the course with a 70% or greater. Complete the evaluation for your selected course. Print your Certificate CE s will automatically be reported to the CE Broker Multiple Sclerosis Purpose The purpose of this continuing education course is to educated health care professional about Multiple Sclerosis. In addition to help nursing professional to understand the signs and symptoms, treatment, and resources available for the patient to live a productive life. Objectives 1. Understand the Pathophysiology and etiology of Multiple Sclerosis. 2. List the types of relapsing MS 3. Describe the risk factors for MS 4. Describe Uhthoff's Syndrome 5. Identify the treatment management of MS 6. List nursing consideration for MS 7. Discuss the patient education for MS
2 Introduction According to Richman, & Schub, (2013) multiple sclerosis (MS) affects an estimated 2.5 million people worldwide, 400,000 in the United States, and 50,000 in Canada. The incidence of MS varies according to one s geographical region. MS can be seem higher in northern locations; per 100,000 population. Common causes of death associated in MS patients includes pneumonia, pulmonary embolism, aspiration, urosepsis, and/or pressure ulcers (Richman, & Schub, (2013); Multiple Sclerosis Association of America (2013). The term Multiple Sclerosis refers to plaques or lesions. These plaques or lesions called MS is an acquired demyelinating disease of the white matter in the brain and spinal cord (Richman, & Schub, 2013). The age of onset of MS is between the ages 20 to 50 however according to Campagnolo (2014) the vast majority of people with MS (approximately 80%) experience their first symptoms by age 40 and is twice as common in women as in men. Campagnolo (2014) further explains that 85% of individuals with MS can present as one of four clinical types: a. Relapsing-remitting (RRMS) b. Primary-progressive (PPMS) c. Secondary-progressive (SPMS) d. Progressive-relapsing (PRMS) RRMS is characterized by acute episodes of exacerbations and remission of neurologic problems that includes: 1. Numbness 2. Loss of voluntary movements in some parts of the body 3. Lack of coordination
3 4. Dizziness 5. Visual disturbances Patient with RRMS has periods of remission. During these periods of remission, patients often recovers from acute episodes of neurological problems that he or she experienced during the exacerbation phases. PPMS is characterized by steady progression of symptoms experienced in the RR stage of MS until the symptoms progress to the phase called secondary progressive (SPMS). SPMS is characterized by progressive neurological deficits, with or without acute attacks. At this point the disease become chronic and it is in this later phase that the cumulative damage to the central nervous system (CNS) begins to result in permanent disability Campagnolo, (2014); Richman, & Schub, (2013). PRMS involves a steady progression of the disease symptoms combined with acute relapses. Relapses are suggested to be associated with the demyelination and inflammation of the white matter of the central nervous system (CNS). Relapses related to MS can range from mild to significant; to disabling for example: The symptoms of PRMS may include: a. Vision problem for example temporary vision lost, eye pain and double vision. b. Heat sensitivity c. Dizziness d. Severe radiating pain in the neck e. Weakness f. Fatigue g. Urosepsis, and UTI due to a neurogenic bladder h. Depression
4 i. Difficulty Concentrating j. Aspiration pneumonia due to dysphagia k. Respiratory failure due to cervical myelopathy or severe demyelination in the brainstem l. Deep vein thrombosis (DVT) related to immobility m. Pressure ulcers due to immobility n. Problems with sexual function o. Muscle Weakness p. Muscle stiffness (Campagnolo, (2014); Richman, & Schub, (2013); Ruto, C. (2013). Relapses The Multiple Sclerosis Association of America (2013) indicates that relapses occurs with relapsing-remitting, progressive-relapsing, and sometimes secondary-progressive forms of MS and characterized by inflammation that occurs along the nerves and the myelin resulting in patients having a temporary worsening or recurrence of existing symptoms and/or the appearance of new symptoms. A relapse can last anywhere weeks to months however neurological signs must be present for at least 24 to 48 hours, without any signs of infection or fever, before the treating physician may consider this type of flare-up to be a true relapse. There is also a term called MS pseudo-exacerbation. MS pseudo-exacerbation can be characterized by a temporary worsening of symptoms without actual myelin inflammation or damage. These symptoms can be brought on by: a. Flu or a virus b. An infection c. Excessive exercise d. Exposure to sunlight or a warm environment for a long period of time
5 e. Depression f. Exhaustion g. Stress. h. Fevers When patients experience MS pseudo-exacerbation symptoms these relapses are usually treated with a high-dose course of powerful corticosteroids over a period of three to five days (Multiple Sclerosis Association of America, 2013). Acthar Gel is another form of treatment. Acthar Gel is a purified form of ACTH. Risk Factors The cause of MS is unknown it is thought to be as result of environmental and genetic factors. There is also thought that that families with first-degree relatives of MS have a 2.5 5% risk of developing the disease, a risk that is times the risk in the general population (Richman, & Schub, 2013). According to the Multiple Sclerosis Association of America (2013) risk factors has also been associated vitamin D deficiencies, and exposure to the Epstein-Barr virus. Parasites tend to weaken the immune response. Therefore, individuals with an increased likelihood for parasitic infection, such as those who live in developing countries, are less likely to be diagnosed with MS, which is triggered by a strong immune response. With improved sanitation and decreased exposure to parasites, the diagnosis of MS is on the rise in these countries. Treatment The goal of treatment for MS is early intervention and treatment that reinforces patients remaining on of one of the long-term disease modifying therapies (DMT) to minimize the rate of conversion from RRMS to secondary-progressive MS (SPMS). However clinical trials are in
6 progress and there are 12 FDA approved long-term treatment medications for early intervention are as follows: Long-Term Disease Modifying Therapy (DMT) Self-injection: Avonex (interferon beta-1a) Betaseron (interferon beta-1b) Copaxone (glatiramer acetate) Extavia (interferon beta-1b) Plegridy (peginterferon beta-1a) Rebif (interferon beta-1a) Intravenous infusion: Lemtrada (alemtuzumab) Novantrone (mitoxantrone) Tysabri (natalizumab) Orally: Aubagio (oral teriflunomide) Gilenya (fingolimod) Tecfidera (dimethyl fumarate or DMF, formerly known as BG-12) When an individual has a more progressive form of MS, interventions are aimed at treating the individual symptoms with the use of medication and improving the quality of life. The following medication are key in treating MS symptoms: Symptoms Treatment Acute pseudoexacerbations dexamethasone, methylprednisolone, adreno- corticotropic hormone (ACTH), prednisone Relapses Fatigue amantadine, fluoxetine, modafinil Spasticity baclofen, dantrolene, diazepam, tizanidine Constipation bisacodyl, docusate, glycerin, magnesium hydroxide Pain carbamazepine, clonazepam, gabapentin, phenytoin Erectile dysfunction alprostadil, sildenafil, tadalafil, vardenafil Depression Urinary tract infection Bladder dysfunction bupropion, citalopram, duloxetine, paroxetine, sertraline ciprofloxacin, methenamine, sulfamethoxazole + trimethoprim imipramine, desmopressin, oxybutynin, prazosin, tamsulosin
7 Tremor Isoniazid, buspirone, propranolol Walking Dalfampridine Multiple Sclerosis Association of America, (2013); National Multiple Sclerosis Society, (2010) Uhthoff's Syndrome Uhthoff's syndrome is usually one of the first symptoms of experienced by patient when diagnosed with MS. Uhthoff s Syndrome can be described as a dimming or reduction in vision, usually associated with exercise or overheating. However one case study involving a male patient described Uhthoff s Syndrome as temporary vision lost while driving to work at six AM. When partial myelin damage along the optic nerve occurs with the disease vision loss is experienced. In addition when an individual temperature increase the ability to conduct nerve impulses along damaged nerves is reduced (Multiple Sclerosis Association of America, 2013). When the individual body temperature is reduce the vision improves. According to the Multiple Sclerosis Association of America, (2013) the treatment for Uhthoff s Syndrome is to reduce the body temperature, and for individual to avoid overheating. Alternative or Complementary Treatment Complementary and alternative therapy is very popular among patients with MS. Nonetheless these popular alternative therapies are unproven by clinical trials, therefore patients should be cautious when using alternative types of therapies. Individual patients who practice their religious faith, aromatherapy, electromagnetic therapy, massage, acupuncture, and herbal remedies may benefit specific symptoms, such as valerian for insomnia or cranberry for prevention of UTIs, but others may irritate the urinary tract, interact with steroid medications, or stimulate the immune system (Reitman & Kalb, 2012). Naltrexone is an approved medication by
8 the United States Food and Drug Administration (FDA) for the treatment of addictions to opioids and alcohol. At the full recommended dose, Naltrexone blocks opioid docking sites on cells (National Multiple Sclerosis Society, 2010). However Naltrexone at significantly lower doses has also been suggested as an alternative therapy, and studies indicate that it improves the client s quality of life but has no impact on physical symptoms (Cree, Kornyeyeva, & Goodin, 2010). Nursing Considerations When Caring for the MS Patients Nursing care for aging clients with MS should focus on helping the client meet needs that allow them to have a productive life, have access to continuum health care, function independently, and social interaction. The nursing care should be focused around a holistic approach in helping the patient to achieve activities of daily living for example: a. Mobility b. Assistive Devices c. Social Activities (Horseback riding, skiing, and daily walking) d. Maintaining Independence e. Referring Home Health Care f. Referring to Adult Living Facilities g. Range of Motion Exercises h. Watching for depression i. The nurse should also assist older clients with MS by teaching them: 1. Coping skills 2. Monitoring their disease progression
9 3. Planning and prioritizing activities 4. Participating in the community activities (DiLorenzo, 2011). j. The nurse should keep the patient informed about appropriate healthcare services such as: 1. Physical therapy 2. Ophthalmology care 3. Support groups 4. Physical and wellness promotion programs Patient Education Patients with early onset of MS has the potential to live a productive life with this disease for many years. Therefore, the nurse should educate the patient to understand the essential of MS, and its implications. Teaching topics for the patient should include the following: a. The overall pathophysiology of the disease b. Classifications of clinical type c. Pseudo-exacerbation and causes d. Symptoms commonly experienced by clients with MS e. Medications and treatment options f. Medications and side effects g. Medication schedule h. Medication Dosages i. Common medication and drug interactions j. How to prevent exacerbations of MS k. Getting plenty of rest during activities l. Avoiding prolong exposure to heat of cold temperatures
10 m. Managing fatigue and stress n. Avoiding physical overexertion o. Avoiding infections p. Explain the precautions for women of childbearing ages and desires to become pregnant q. Available resources such as the National Multiple Sclerosis Society. Conclusion Living with a chronic illness can be very difficult. Intervention should be aim at early treatment to stop the progression of MS and to live a productive life. According to the Multiple Sclerosis Association of America, (2013) early treatment and staying on one of the long-term DMTs for MS may also delay the rate of conversion from RRMS to secondary-progressive MS (SPMS). Nursing intervention should continue to focus on referring the patient that will include a multidisciplinary approach, and educating the patient about resources that are available for them to live a productive life.
11 References Cree, B., Goodin, D., Kornyeyeva. (2010). Low Dose Naltrexone. Annals of Neurology, 68(2), DiLorenzo, T. (2011) Aging with Multiple Sclerosis. Clinical Bulletin. Information for heath Professionals. Retrieved from Clinical_Bulletin_Aging_with_MS.pdf Mayo Clinic. (2012). Multiple sclerosis: Treatments and drugs. Retrieved from Multiple Sclerosis Association of America. (2013a). What are the Symptoms of MS. Retrieved from Multiple Sclerosis Association of America. (2013b). Uhthoffs Syndrome. Retrieved from Multiple Sclerosis Association of America. (2013c). Treatments for MS. Retrieved from National Institute of Neurological Disorders and Stroke. (2012). Multiple sclerosis: Hope through research. Retrieved from /detail_ multiple_sclerosis.htm# National Multiple Sclerosis Society (2010). Low Dose Naltrexone. Retrieved from DS00188/DSECTION=treatmentsand-drugs. Medicines/Low-Dose-Naltrexone.
12 Reitman, N., & Kalb, R. (2012). Multiple sclerosis: The nursing perspective (6th ed.). New York, NY: National Multiple Sclerosis Society. Richman, S., & Schub, T. (2013). Multiple Sclerosis.retrieved from Cinahl. Roohani, Pezhman et al. (2010. Multiple Sclerosis and Related Disorders, 3,(4), Ruto, C. (2013). Special Needs Populations: Care of Patients with Multiple Sclerosis. AORN Journal, 98(3), doi: /j.aorn
Progress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
More informationInformation about medicines for multiple sclerosis
Information about medicines for multiple sclerosis Information about medicines for multiple sclerosis What is multiple sclerosis? 1 Multiple sclerosis (MS) is a lifelong disease that affects your brain
More informationInformation About Medicines for Multiple Sclerosis
Information About Medicines for Multiple Sclerosis Information About Medicines for Multiple Sclerosis What is multiple sclerosis? 1 Multiple sclerosis (MS) is a lifelong disease that affects your brain
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationMultiple Sclerosis: What You Need To Know. For Professionals
Multiple Sclerosis: What You Need To Know For Professionals What will I learn today? The Basics: What is MS? Living with MS: A Family Affair We Can Help: The National MS Society What MS Is: MS is thought
More informationWhat is Multiple Sclerosis? Gener al information
What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationManaging the Symptoms of Multiple Sclerosis. Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner
Managing the Symptoms of Multiple Sclerosis Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner What is Multiple Sclerosis An autoimmune disease that affects the central nervous system (CNS) The immune
More informationIntegrating New Treatments: A Case Based Approach
Integrating New Treatments: A Case Based Approach JILL CONWAY, MD, MA, MSCE DIRECTOR, MS CENTER DIRECTOR, NEUROLOGY CLERKSHIP AT UNCSOM- CHARLOTTE CAMPUS CAROLINAS HEALTHCARE CENTER Objectives Provide
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationLemtrada (alemtuzumab)
Lemtrada (alemtuzumab) Policy Number: 5.02.517 Last Review: 08/2015 Origination: 08/2015 Next Review: 08/2016 Policy BCBSKC will provide coverage for Lemtrada (alemtuzumab) when it is determined to be
More informationMedication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014
Medication Policy Manual Policy No: dru376 Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective
More informationWhat is MS? 1. disease that affects the central nervous. Is a disease that affects both white and gray matter
What is MS? 1 Neuron Damaged myelin due to inflammation MS is a chronic immunemediated disease that affects the central nervous system (CNS) Is a disease that affects both white and gray matter Interrupted
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationMultiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center
Multiple Sclerosis Update Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center None Disclosures First of All. Why is my talk in the Neurodegenerative hour? I respectfully object! Case
More informationMedications for MULTIPLE SCLEROSIS Student Version
Medications for MULTIPLE SCLEROSIS Student Version DEH 2300 Valencia Community College Summer: 2006-14 Sandra C. Pendergraft DEFINITION / PATHOPHYSIOLOGY Chronic, frequently progressive disease of CNS
More informationPCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft 3-27-15
PCORI Workshop on Treatment for Multiple Sclerosis Breakout Group Topics and Questions Draft 3-27-15 Group 1 - Comparison across DMTs, including differential effects in subgroups Consolidated straw man
More informationMedication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010
Medication Policy Manual Policy No: dru229 Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationWhich injectable medication should I take for relapsing-remitting multiple sclerosis?
Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationCNS DEMYLINATING DISORDERS
CNS DEMYLINATING DISORDERS Multiple sclerosis A Dutch saint named Lidwina, who died in 1433, may have been one of the first known MS patients. After she fell while ice skating, she developed symptoms such
More informationRelapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
More informationMultiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate.
What is Multiple Sclerosis? Multiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate. A disease of the central nervous system
More informationChoices Drug Therapies
Choices Drug Therapies There are many prescription drugs available to treat MS. There are disease modifying drugs that affect the long-term course of MS and other medications to treat a particular symptom.
More informationPatient Group Input to CADTH
Patient Group Input to CADTH Section 1 General Information Name of the drug CADTH is reviewing and indication(s) of interest Name of patient group/author of submission Patient group s contact information:
More informationHow to S.E.A.R.C.H. for the Right MS Therapy for You!
How to S.E.A.R.C.H. for the Right MS Therapy for You! How to S.E.A.R.C.H. for the Right MS Therapy for You! Copyright Multiple Sclerosis Association of America, 2012. All rights reserved. This booklet
More informationMedication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004
Medication Policy Manual Policy No: dru108 Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective
More informationNew Treatment Options for MS Patients: Understanding risks versus benefits
New Treatment Options for MS Patients: Understanding risks versus benefits By Michael A. Meyer, MD Department of Neurology, Sisters Hospital, Buffalo, NY Objectives: 1. to understand fundamentals of MS
More informationA Definition of Multiple Sclerosis
English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:
More informationA neurologist would assess your eligibility and suitability for the DMTs.
Choices Disease Modifying Treatments Disease modifying treatments (DMTs) are medications which modify the disease course. They target inflammation and are designed to reduce the damage caused by relapses.
More informationDisease Modifying Therapies (DMTs) in Multiple Sclerosis
Disease Modifying Therapies (DMTs) in Multiple Sclerosis Gary Stobbe, MD Medical Director, MS Project ECHO Clinical Assistant Professor, UW Neurology Conflict of Interest Dr. Stobbe has no conflicts of
More informationInsight. Drug Class. Background, new developments, key strategies. Introduction. Faulty signals. 400,000 patients in the US 1
Drug Class Insight Multiple Sclerosis Background, new developments, key strategies Introduction 400,000 patients in the US 1 Most people diagnosed between age 20 50 2 2-3x more women than men get MS 2
More informationUnderstanding. Multiple Sclerosis. Tim, diagnosed in 2004.
Understanding Multiple Sclerosis Tim, diagnosed in 2004. What Is Multiple Sclerosis? Multiple sclerosis (MS) is a neurologic disorder that affects the central nervous system (CNS). The CNS includes the
More informationMany people with MS use some form of conventional medical treatment, and many people also use complementary and alternative medicine (CAM).
Complementary and alternative medicine (CAM) CAM therapies can generally be divided into the following categories: Biologically based therapies (eg, dietary supplements, diets, bee venom therapy, hyperbaric
More informationCoping with Symptoms of Multiple Sclerosis
Coping with Symptoms of Multiple Sclerosis Josée Poirier B. Sc. Nursing, MSCN Outline What Is a Pseudo exacerbation? Awareness Advancement of Treatments Treatment of Symptoms Uhthoff s Phenomenon What
More informationOptic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain.
Optic Neuritis Your doctor thinks that you have had an episode of optic neuritis. This is the most common cause of sudden visual loss in a young patient. It is often associated with discomfort in or around
More informationUnderstandi your multipl sclerosis medications URAC. All Walgreens specialty pharmacy locations are ACHC and URAC accredited.
Understandi your multipl sclerosis medications URAC All Walgreens specialty pharmacy locations are ACHC and URAC accredited. Table of contents Multiple sclerosis medications: an overview...1 Staying on
More information06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute
The Impact of Multiple Sclerosis in the Pacific Northwest James Bowen, MD Multiple Sclerosis Center Multiple Sclerosis Center Swedish Neuroscience Institute 1 2 Motor Symptoms of MS Weakness Spasticity
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru381 Topic: Lemtrada TM, alemtuzumab Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationNovel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?
Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International
More informationThe MS Disease- Modifying Drugs. Gener al information
The MS Disease- Modifying Drugs Gener al information Current as of October 30, 2009. This online version is updated as breaking news requires. If you have downloaded and printed a copy from the web, please
More informationA Letter From the MS Coalition
0 A Letter From the MS Coalition The treatment of multiple sclerosis (MS) requires a comprehensive management strategy. One important component of that strategy is modifying the disease course. When deciding
More informationConflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011
Conflict of Interest Declaration Overview of New Medications for Multiple Sclerosis I or my spouse have no actual or potential conflict of interest in relation to this activity. Crystal Obering, Pharm.D.,
More informationWe move our mission forward through Client Education & Services, Research, Advocacy and Professional Education.
1 It is the National MS Society s mission to mobilize people and resources to drive research for a cure and to address the challenges of everyone affected by MS. The National MS Society, Greater Northwest
More informationUnderstanding your Tecfidera treatment
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS
More informationUnderstanding your Tecfidera treatment
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS
More informationAll About Multiple Sclerosis
Multiple Sclerosis Association of America All About Multiple Sclerosis Third Edition MSAA MSAA All About Multiple Sclerosis Written by: Susan Wells Courtney Edited by: Jack Burks, M.D. Andrea Borkowski
More informationHow to S.E.A.R.C.H. SM for the Right MS Therapy For You!
How to S.E.A.R.C.H. SM for the Right MS Therapy For You! The Changing Landscape The first treatment for relapsing-remitting multiple sclerosis (RRMS) was approved by the United States Food and Drug Administration
More informationThere's no cure for multiple sclerosis. However treatments can help treat attacks, modify the course of the disease and treat symptoms.
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
More informationMultiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON
Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON First-line DMTs Reduce Relapse Frequency by ~30% vs. Placebo Frequency of relapse with various DMTs, based
More informationStudy Support Materials Cover Sheet
Study Support Materials Cover Sheet Document Title ESCALATE Patient Brochure Intended Audience This brochure is designed to be given to potentially eligible patients as a take-home summary of key information
More informationChoices Primary Progressive MS (PPMS)
Choices Primary Progressive MS (PPMS) What is primary progressive MS? Approximately 10% of people with MS worldwide are told they have primary progressive MS a form of MS where from the very first symptoms,
More informationThe MS Disease- Modifying Medications
The MS Disease- Modifying Medications National MS Society 1 Current as of November 2014. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication,
More informationUnderstanding How Existing and Emerging MS Therapies Work
Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of
More informationMultiple Sclerosis Drug Discoveries - What the Future Holds
Brochure More information from http://www.researchandmarkets.com/reports/1408035/ Multiple Sclerosis Drug Discoveries - What the Future Holds Description: The recent approval in the US of Novartis' orally
More informationThe MS Disease- Modifying Medications GENERAL INFORMATION
The MS Disease- Modifying Medications GENERAL INFORMATION Current as of March 2014. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication, please
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationMuscular Dystrophy and Multiple Sclerosis. ultimately lead to the crippling of the muscular system, there are many differences between these
Battles 1 Becky Battles Instructor s Name English 1013 21 November 2006 Muscular Dystrophy and Multiple Sclerosis Although muscular dystrophy and multiple sclerosis are both progressive diseases that ultimately
More informationSECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage
SECTION 2 Multiple Sclerosis (MS) Drug Coverage Section 2 Multiple Sclerosis (MS) Drug Coverage ALBERTA HEALTH AND WELLNESS DRUG BENEFIT LIST Selected Drug Products used in the treatment of patients with
More informationhttp://images.tutorvista.com/content/control5coordination/human5brain.jpeg!! 387
http://images.tutorvista.com/content/control5coordination/human5brain.jpeg!! 387! 388! http://my.fresnounified.org/personal/lygonza/gonzalez/neuron/neuron5synapse%20communication.png!! http://www.urbanchildinstitute.org/sites/all/files/databooks/2011/ch15fg25communication5between5neurons.jpg!!
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationNew treatments in MS What s here and what s nearly here
5 th MS Research Day, June 14 th 2014 New treatments in MS What s here and what s nearly here David Miller Queen Square MS Centre at UCL and UCLH Course of MS and its treatment Relapsing remitting Disability
More informationMultiple Sclerosis (MS)
Multiple Sclerosis (MS) Purpose/Goal: Care partners will have an understanding of Multiple Sclerosis and will demonstrate safety and promote independence while providing care to the client with MS. Introduction
More informationThe MS Disease- Modifying Medications
The MS Disease- Modifying Medications National MS Society 1 Current as of January 2015. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication,
More informationNational Multiple Sclerosis Society. Disease Modification in Multiple Sclerosis. Current as of January 2, 2013
National Multiple Sclerosis Society Disease Modification in Multiple Sclerosis Current as of January 2, 2013 Since 1993, the U.S. Food and Drug Administration (FDA) has approved several medications for
More informationNHS BOURNEMOUTH AND POOLE AND NHS DORSET
NHS BOURNEMOUTH AND POOLE AND NHS DORSET COMMISSIONING STATEMENT ON THE USE OF BETA-INTERFERON IN RELAPSING-REMITTING MULTIPLE SCLEROSIS OR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, WHERE RELAPSES ARE
More informationResources for the Patient. Please print these out and give them to your patients with MS
Resources for the Patient Please print these out and give them to your patients with MS An internet program for persons with MS on the FCM website Multiple Sclerosis: A Toolbox of Information and Resources
More informationTaylor Slotte Pathology Disease Report Spring 2014 Multiple Sclerosis
Taylor Slotte Pathology Disease Report Spring 2014 Multiple Sclerosis Abstract Multiple sclerosis (MS) is a chronic autoimmune disorder that attacks the body s central nervous system. It affects the brain,
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationLife with MS: Striving for Maximal Independence & Fulfillment
Life with MS: Striving for Maximal Independence & Fulfillment St. Louis, May 7, 2005 Florian P. Thomas, MA, MD, PhD MS Center, Department of Neurology Associate Professor, Saint Louis University Brain
More informationTreatments for MS: Immunotherapy. Gilenya (fingolimod) Glatiramer acetate (Copaxone )
Treatments for MS: Immunotherapy There are currently several disease-modifying therapies approved for people with MS in Australia. These therapies, called immunotherapies, work to reduce disease activity
More informationAUBAGIO (teriflunomide) oral tablet
AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationSOUTH TAMPA MULTIPLE SCLEROSIS CENTER PATIENT/ CARE GIVER QUESTIONNAIRE
SOUTH TAMPA MULTIPLE SCLEROSIS CENTER PATIENT/ CARE GIVER QUESTIONNAIRE DEMOGRAPHIC INFORMATION Patient Name: Date: Address: City: State: Zip Code Best Phone Number: Marital Status Phone (H): (W) (Cell):
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Daclizumab for treating relapsing-remitting multiple Draft scope (pre-referral) Draft remit/appraisal objective To
More informationMultiple Sclerosis (MS) Class Update
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Multiple Sclerosis (MS) Class Update Month/Year of
More informationOxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients
Oxford University Hospitals NHS Trust Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis Information for patients page 2 What is Natalizumab and what is it used for? Natalizumab is an
More informationStepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU
FOR MS RELAPSES Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU As a person with multiple sclerosis (MS), you know firsthand the profound impact MS relapses can have on your
More informationThere are several types of diagnosable MS including the following, though several more may be possible. Each type may be mild, moderate or severe.
Treatment strategies for patients diagnosed with Multiple Sclerosis Alison Loercher, MAOM, L.Ac. American Herbalists Guild Annual Symposium, October 2015 Multiple Sclerosis (MS) is an autoimmune disease
More informationUnderstanding The Unique Aspects And Challenges Of Living With MS
Connecticut Resident Services Coordinator Training Understanding The Unique Aspects And Challenges Of Living With MS July 23, 2009 Susan Raimondo, Senior Director, Advocacy & Programs National Multiple
More informationRelapsing remitting MS
An introduction to Relapsing remitting MS What does it mean when you are diagnosed with relapsing remitting MS? There are three main types of MS: relapsing remitting MS, primary progressive MS and secondary
More informationMULTIPLE SCLEROSIS Management and Therapy
MULTIPLE SCLEROSIS Management and Therapy 115 th Oklahoma Osteopathic Association Annual Convention April 30 th, 2015 Anthony J. Vaughn, M.D. ANTHONY J. VAUGHN, M.D. Assistant Professor Director, Clinical
More informationUsing the MS Clinical Course Descriptions in Clinical Practice
Using the MS Clinical Course Descriptions in Clinical Practice Mark J. Tullman, MD Director of Clinical Research The MS Center for Innovations in Care Missouri Baptist Medical Center Disclosures Consultant/speaking
More informationPublished by MSAA in March 2013
Published by MSAA in March 2013 Improving Lives Today! MSAA s MS Research Update is published annually as a service to the MS community. For additional information about MS as well as MSAA s programs and
More informationPharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022. Multiple
Brochure More information from http://www.researchandmarkets.com/reports/2541548/ PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022 Description: PharmaPoint: Multiple
More informationSurvey of 267 Patients Using Low Dose Naltrexone for Multiple Sclerosis
Survey of 267 Patients Using Low Dose Naltrexone for Multiple Sclerosis Summary In order to stimulate interest among other academic researchers in LDN trials for MS, an online patient tracking system has
More informationKnowledge Brochure Series MS & SYMPTOM MANAGEMENT
Knowledge Brochure Series MS & SYMPTOM MANAGEMENT Identifying your multiple sclerosis (MS) symptoms 1 A chronic disease like MS can cause a number of different symptoms and spotting yours is the first
More informationTreatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD
Treatment in Relapsing MS: Choosing Among the Options Donald Negroski, MD Disclosures Research Grants Educational activities and lectures Consulting or other services including Continuing Medical Education
More informationGrowth in revenue from MS drugs has been driven largely by price increases over the last several years.
March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera
More informationThe Many Faces of MS
The Many Faces of MS Patricia A. Modica, OD, FAAO SUNY College of Optometry Kelly Malloy, OD, FAAO Pennsylvania College of Optometry at Salus University Multiple Sclerosis (MS) Most common acquired disease
More informationA Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market
A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies NEC3-52 November 2014 Contents
More informationThe Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences
The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for
More informationAUBMC Multiple Sclerosis Center
AUBMC Multiple Sclerosis Center 1 AUBMC Multiple Sclerosis Center The vision of the American University of Beirut Medical Center (AUBMC) is to be the leading academic medical center in Lebanon and the
More informationDrug Class Review Disease-modifying Drugs for Multiple Sclerosis
Drug Class Review Disease-modifying Drugs for Multiple Sclerosis Final Update 3 Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness
More informationMULTIPLE SCLEROSIS. Megan Snyder INTRODUCTION TO EPIDEMOLOGY
MULTIPLE SCLEROSIS Megan Snyder INTRODUCTION TO EPIDEMOLOGY Snyder 1 Personal Connection to Multiple Sclerosis Multiple sclerosis (MS) is an extremely painful disease of which not enough is understood.
More informationPublished by MSAA in February 2014
Published by MSAA in February 2014 VITAMIN D MSAA s MS Research Update is published annually as a service to the MS community. This update provides an overview of the research behind the approved and experimental
More informationDisease modifying drug therapy
Disease modifying drug therapy New edition for 2014-15 We hope you find the information in this book helpful. If you would like to speak with someone about any aspect of MS, contact the MS Trust information
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationNew Developments in the Treatment and Management of Multiple Sclerosis
New Developments in the Treatment and Management of Multiple Sclerosis Myla D. Goldman, MD, MS For a CME/CEU version of this article, please go to www.namcp.org/cmeonline.htm, and then click the activity
More informationPROPOSED REVISIONS TO THE CRITERIA. multiple sclerosis (RRMS)] Chapter 6 6 It is recognised that use is in only exceptional circumstances in RRMS.
Specialist Working Group for Neurology Proposed changes to the Criteria for the clinical use of intravenous immunoglobulin in Australia, Second Edition ITEM Condition Name Multiple Sclerosis (MS) Multiple
More informationDisclosure Statement. Multiple Sclerosis: Current Trends in Treatment. Epidemiology of MS. Multiple Sclerosis. Viral Link to MS.
Disclosure Statement Multiple Sclerosis: Current Trends in Treatment Member of Speaker s Bureau Biogen Idec Will discuss non FDA approved therapies Christine St Laurent MSN, RN, MSCN 19 th Annual Mud Season
More information